Link William Phd Purchases 37,037 Shares of RxSight, Inc.

On June 17, 2026, Link William Phd purchased 37,037 shares of RxSight, Inc. (NasdaqGM: RXST). This insider transaction did not involve a planned trading program. The insider buying reflects a notable acquisition in the medical devices company focused on cataract surgery technology.

Other Institutional Activity in RxSight, Inc.

Several institutional investors have recently adjusted their positions in RxSight, Inc. BlackRock, Inc. increased its holdings by 482,086 shares, bringing its total to 3,187,092 shares valued at approximately $19.63 million. Millennium Management LLC and Artisan Partners Limited Partnership both reduced their holdings, with Millennium Management trimming 69,579 shares to 2,059,459 shares worth about $12.69 million, and Artisan Partners reducing by 98,580 shares to 2,058,684 shares valued at roughly $12.68 million. No Street GP LP slightly increased its position by 25,000 shares, ending with 2,000,000 shares valued at $12.32 million.

RxSight, Inc. Stock Snapshot

Shares of RxSight, Inc. (NasdaqGM: RXST) are currently trading around $4.73. The company, with a market cap of approximately $195.8 million, operates in the healthcare sector, specifically in the medical devices industry. Despite a lack of profitability, resulting in no meaningful P/E ratio, the company's forward P/E is -8.45. RxSight has a beta of 1.134, indicating moderate volatility compared to the market. The stock's 52-week range is between $4.48 and $14.25, with a 50-day moving average of $6.09 and a 200-day moving average of $8.36. The firm's current ratio stands at a robust 10.2, with a quick ratio of 8.779 and a debt-to-equity ratio of 4.05.

Recent Earnings

RxSight reported revenue of $127.5 million, though it experienced a revenue decline of 18.5%. The company has a negative net margin of 36.6% and a return on equity of -17.1%. The next earnings release is scheduled for August 6, 2026.

Insider Buying and Selling at RxSight, Inc.

On June 17, 2026, several insiders, including Juliet Tammenoms Bakker, Robert Keith Warner, Robert Palmisano, Link William Phd, Shweta Maniar, and Jesse Anderson Corley, each purchased 37,037 shares of RxSight, Inc. These transactions were not part of any planned trading programs.

Analysts Set New Price Targets

On May 7, 2026, Wells Fargo maintained a hold rating with a price target of $9.00. Needham also maintained its buy rating, setting a target at $11.00. The overall analyst consensus for RxSight, Inc. is mixed, with a mean price target of $8.79 based on seven analyst opinions.

About RxSight, Inc.

RxSight, Inc. is a medical technology company based in Aliso Viejo, California. It specializes in light adjustable intraocular lenses (LAL) used in cataract surgery. The company offers the RxSight system, which includes an intraocular lens made from photosensitive material that can be adjusted post-surgery using ultraviolet light. This technology allows for customization of visual acuity for patients, enhancing their vision after cataract surgery. RxSight, Inc., led by CEO Dr. Ronald M. Kurtz, employs 461 people.

Bottom Line

The recent insider buying activity by Link William Phd and other insiders at RxSight, Inc. highlights an interesting development in the company's ownership. Investors often track such moves for insights into management's confidence. However, it's important to remember that insider transactions are backward-looking and may not reflect current sentiment. As RxSight continues to navigate the medical devices sector, its financial performance and analyst ratings will be key areas to watch.